|
Dan Strieter, MS |
|
Mr. Strieter has more than 15 years consulting and pharmaceutical development experience. In addition to consulting on biostatistical issues, he also serves as a member of the company’s Pharmacometrics group contributing to projects involving the development of clinical trial simulations as well as PK/PD modeling. Mr. Strieter also manages GLDD’s QA efforts. He most recently served as a consultant to deCODE Genetics, primarily focused on the antiplatelet development program. Prior to his consulting work, Mr. Strieter was a Clinical Statistician at Pfizer where he provided statistical support across a broad range of therapeutic areas. While at Pfizer, he supported both clinical pharmacology Phase I studies as well as larger Phase III registration studies. His interest in QT analysis led to assisting in developing guidelines for collection and analysis of QT data for all Pfizer clinical trials. Mr. Strieter also has experience working for a large CRO, gaining international experience with a stint in Sweden. He received his MS in Statistics from the University of Tennessee, Knoxville. |
